<DOC>
	<DOCNO>NCT00814606</DOCNO>
	<brief_summary>This study seek evaluate safety efficacy take fluvastatin along peginterferon alfa previous partial responder genotype 1 HCV .</brief_summary>
	<brief_title>A Pilot Trial Determine Safety Efficacy Fluvastatin Previous Partial Responders Pegylated Interferon Ribivirin Patients With Genotype 1 Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Male female ethnicity age 18 65 year genotype 1 HCV Previous partial responder attempt HCV therapy PEG/RBV ( least 1 log drop le 2 log drop HCV RNA 12 week ) Previous history serum HCVRNA PCR quantifiable Roche Amplicore HCV Test A liver biopsy within 3 year study enrollment consistent HCV disease . Compensated liver disease , ChildPugh Class ≤ 6 Negative urine pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All patient enrol study partner study participant childbearing potential must use two reliable form effective contraception study . Exceptions may include partner/participant surgically sterile . Willingness comply study procedure provide write informed consent AST ALT &gt; 10 ULN Any investigational drug ≤ 12 week prior first study drug Prior intolerance statin medication Previous serious side effect IFN RBV ( e.g . psychiatric side effect necessitate treatment discontinuation , severe cytopenia refractory growth factor , intolerance IFN/RBV require treatment discontinuation ) Any systemic antiviral therapy ≤ 24 week prior first dose study drug expectation treatment need time study . Exception : Patients take expected require treatment herpetic lesion Positive test screen antiHAV IgM Ab , HBsAg , antiHBcIgM Ab , antiHIV Ab Serum concentration cerulplamin alph1antitrypsin consistent increase risk metabolic liver disease History evidence medical condition associate chronic liver disease ( e.g . hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure , nonalcoholic steatohepatitis ) Women pregnant breastfeed male partner woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>genotype 1 hepatitis C</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>liver</keyword>
</DOC>